TY - JOUR
T1 - HDL Composition, Heart Failure, and Its Comorbidities
AU - Diab, Ahmed
AU - Valenzuela Ripoll, Carla
AU - Guo, Zhen
AU - Javaheri, Ali
N1 - Funding Information:
AJ was supported by R01 HL155344 and K08HL138262 from the NHLBI and by the Diabetes Research Center at Washington University in St. Louis of the National Institutes of Health under award number P30DK020579, as well as the NIH grant P30DK056341 (Nutrition Obesity Research Center), and by the Children's Discovery Institute of Washington University (MC-FR-2020-919) and St. Louis Children's Hospital. ZG was supported by the American Heart Association Postdoctoral Fellowship (898679).
Funding Information:
AJ has a patent for fusion protein nanodiscs and lipase inhibitors for the treatment of heart failure and has received grant support from AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher Copyright:
Copyright © 2022 Diab, Valenzuela Ripoll, Guo and Javaheri.
PY - 2022/3/8
Y1 - 2022/3/8
N2 - Although research on high-density lipoprotein (HDL) has historically focused on atherosclerotic coronary disease, there exists untapped potential of HDL biology for the treatment of heart failure. Anti-oxidant, anti-inflammatory, and endothelial protective properties of HDL could impact heart failure pathogenesis. HDL-associated proteins such as apolipoprotein A-I and M may have significant therapeutic effects on the myocardium, in part by modulating signal transduction pathways and sphingosine-1-phosphate biology. Furthermore, because heart failure is a complex syndrome characterized by multiple comorbidities, there are complex interactions between heart failure, its comorbidities, and lipoprotein homeostatic mechanisms. In this review, we will discuss the effects of heart failure and associated comorbidities on HDL, explore potential cardioprotective properties of HDL, and review novel HDL therapeutic targets in heart failure.
AB - Although research on high-density lipoprotein (HDL) has historically focused on atherosclerotic coronary disease, there exists untapped potential of HDL biology for the treatment of heart failure. Anti-oxidant, anti-inflammatory, and endothelial protective properties of HDL could impact heart failure pathogenesis. HDL-associated proteins such as apolipoprotein A-I and M may have significant therapeutic effects on the myocardium, in part by modulating signal transduction pathways and sphingosine-1-phosphate biology. Furthermore, because heart failure is a complex syndrome characterized by multiple comorbidities, there are complex interactions between heart failure, its comorbidities, and lipoprotein homeostatic mechanisms. In this review, we will discuss the effects of heart failure and associated comorbidities on HDL, explore potential cardioprotective properties of HDL, and review novel HDL therapeutic targets in heart failure.
KW - apolipoprotein A-I
KW - apolipoprotein M
KW - cardiomyopathy
KW - heart failure
KW - high-density lipoprotein (HDL)
KW - sphingosine-1-phosphate
UR - http://www.scopus.com/inward/record.url?scp=85130854020&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2022.846990
DO - 10.3389/fcvm.2022.846990
M3 - Review article
C2 - 35350538
AN - SCOPUS:85130854020
SN - 2297-055X
VL - 9
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
M1 - 846990
ER -